ALICE BURRESS: Open Payments
NPI 1033151097 · ATLANTIS, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,564 in 133 payments from 27 companies in 2025. Trend: 2023 $2,796 · 2024 $4,418 · 2025 $4,564
Food & beverage: $4,564
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 46 | $1,061 |
| Eisai Inc. | 14 | $454 |
| Neurocrine BioSciences, Inc. | 10 | $415 |
| Gilead Sciences, Inc. | 2 | $260 |
| Novo Nordisk Inc | 2 | $250 |
| UCB, Inc. | 7 | $225 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $191 |
| Otsuka America Pharmaceutical, Inc. | 4 | $184 |
| Lilly USA, LLC | 8 | $150 |
| Merz Pharmaceuticals, LLC | 2 | $146 |
Products named: LEQEMBI, INGREZZA, UBRELVY, QULIPTA, BOTOX, Wegovy, REXULTI, HYQVIA.
Industry payments across FL — which companies pay providers there.
